Cencora, Inc. $COR Shares Purchased by Clark Capital Management Group Inc.

Clark Capital Management Group Inc. boosted its position in Cencora, Inc. (NYSE:COR) by 2.0% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 251,467 shares of the company’s stock after acquiring an additional 4,924 shares during the period. Clark Capital Management Group Inc.’s holdings in Cencora were worth $78,591,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. increased its stake in Cencora by 13.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock valued at $15,086,000 after purchasing an additional 5,543 shares during the last quarter. AustralianSuper Pty Ltd acquired a new stake in Cencora in the 3rd quarter worth about $26,191,000. Mediolanum International Funds Ltd boosted its stake in Cencora by 133.0% in the 3rd quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock worth $17,342,000 after buying an additional 32,138 shares during the last quarter. Advisors Asset Management Inc. grew its holdings in Cencora by 40.3% in the 3rd quarter. Advisors Asset Management Inc. now owns 17,302 shares of the company’s stock valued at $5,407,000 after buying an additional 4,973 shares during the period. Finally, Rhumbline Advisers grew its holdings in Cencora by 4.0% in the 3rd quarter. Rhumbline Advisers now owns 430,150 shares of the company’s stock valued at $134,435,000 after buying an additional 16,539 shares during the period. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, EVP Elizabeth S. Campbell sold 3,351 shares of the business’s stock in a transaction dated Friday, December 19th. The stock was sold at an average price of $342.10, for a total value of $1,146,377.10. Following the transaction, the executive vice president owned 23,891 shares in the company, valued at approximately $8,173,111.10. The trade was a 12.30% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, EVP Silvana Battaglia sold 1,677 shares of the stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $345.00, for a total value of $578,565.00. Following the completion of the transaction, the executive vice president directly owned 18,796 shares of the company’s stock, valued at $6,484,620. This represents a 8.19% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 15,220 shares of company stock worth $5,282,867 over the last ninety days. Corporate insiders own 0.38% of the company’s stock.

Wall Street Analysts Forecast Growth

COR has been the topic of several recent analyst reports. Robert W. Baird set a $415.00 price objective on shares of Cencora in a report on Tuesday, January 13th. Wells Fargo & Company boosted their target price on shares of Cencora from $405.00 to $429.00 and gave the company an “overweight” rating in a report on Tuesday, February 10th. Jefferies Financial Group raised shares of Cencora from an “underperform” rating to a “buy” rating in a research report on Thursday, January 22nd. Weiss Ratings raised shares of Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research note on Thursday, February 5th. Finally, Evercore decreased their price target on shares of Cencora from $440.00 to $420.00 and set an “outperform” rating on the stock in a report on Thursday, February 5th. Eleven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat.com, Cencora currently has a consensus rating of “Moderate Buy” and an average target price of $399.00.

Cencora Trading Down 0.8%

COR opened at $349.69 on Friday. The firm’s 50 day moving average is $355.58 and its 200-day moving average is $338.47. Cencora, Inc. has a 52-week low of $252.49 and a 52-week high of $377.54. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62. The firm has a market capitalization of $68.03 billion, a P/E ratio of 42.03, a P/E/G ratio of 1.63 and a beta of 0.68.

Cencora (NYSE:COR) last announced its earnings results on Wednesday, February 4th. The company reported $4.08 earnings per share for the quarter, beating the consensus estimate of $4.04 by $0.04. The business had revenue of $85.93 billion during the quarter, compared to the consensus estimate of $86.12 billion. Cencora had a net margin of 0.50% and a return on equity of 176.54%. The business’s quarterly revenue was up 5.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $3.73 earnings per share. Analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Monday, March 2nd. Shareholders of record on Friday, February 13th were given a $0.60 dividend. This represents a $2.40 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend was Friday, February 13th. Cencora’s dividend payout ratio is presently 28.85%.

Cencora Company Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.